Advertisement

Der Internist

, Volume 59, Issue 12, pp 1268–1278 | Cite as

Was ist gesichert in der Therapie der Glomerulonephritis?

  • J. FloegeEmail author
  • P. Boor
  • M. J. Moeller
Schwerpunkt: Was ist gesichert in der Therapie?
  • 565 Downloads

Zusammenfassung

Glomerulonephritiden stellen praktisch ausnahmslos seltene Erkrankungen dar, sind aber unter anderem der häufigste Grund, warum junge Erwachsene dialysepflichtig werden. Neben der bioptischen, spezifischen Diagnosesicherung stellt die Abschätzung der Prognose einen entscheidenden Schritt dar, da nur so beurteilt werden kann, ob eine vergleichsweise nebenwirkungsarme, aber hocheffektive „supportive“ Therapie ausreichend ist oder ob zusätzlich eine immunsuppressive Behandlung notwendig wird. Letzteres wird hier für die häufigsten europäischen Glomerulonephritisformen diskutiert: Immunglobulin-A-Nephropathie, membranöse Glomerulonephritis, Minimal-change-Nephropathie und fokal-segmentale Glomerulosklerose.

Schlüsselwörter

IgA-Nephropathie Membranöse Nephropathie Minimal-change-Nephropathie Fokal-segmentale Glomerulosklerose Nierenbiopsie 

What is certain in the treatment of glomerulonephritis?

Abstract

Glomerulonephritides essentially all belong to the rare diseases; however, they are the most common cause of end-stage renal disease in young adults. Besides obtaining a specific diagnosis via a renal biopsy, assessing the prognosis constitutes the other essential step in the work-up, since this enables a decision to be made on whether supportive care with relatively few adverse effects is sufficient or whether additional immunosuppressive therapy is required. The latter is discussed focusing on the most common European types of glomerulonephritis: immunoglobulin A nephropathy, membranous glomerulonephritis, minimal change nephropathy and focal segmental glomerulosclerosis.

Keywords

IgA nephropathy Membranous glomerulonephritis Minimal change nephropathy Focal segmental glomerulosclerosis Renal biopsy 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

J. Floege ist als Berater im Rahmen klinischer Studien für Chugai, Calliditas, Omeros, Alnylam und Retrophin tätig. P. Boor und M.J. Moeller geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Anonymous (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2(Supplement 2):139–274Google Scholar
  2. 2.
    Beck LH Jr., Bonegio RG, Lambeau G et al (2009) M‑type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21CrossRefGoogle Scholar
  3. 3.
    Clark WF, Sontrop JM, Huang SH et al (2018) Effect of coaching to increase water intake on kidney function decline in adults with chronic kidney disease: the CKD WIT randomized clinical trial. JAMA 319:1870–1879CrossRefGoogle Scholar
  4. 4.
    Cravedi P, Ruggenenti P, Remuzzi G (2012) Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 8:301–306CrossRefGoogle Scholar
  5. 5.
    Dahan K, Debiec H, Plaisier E et al (2017) Rituximab for severe membranous nephropathy: a 6‑month trial with extended follow-up. J Am Soc Nephrol 28:348–358CrossRefGoogle Scholar
  6. 6.
    De Vriese AS, Glassock RJ, Nath KA et al (2017) A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol 28:421–430CrossRefGoogle Scholar
  7. 7.
    Fellstrom BC, Barratt J, Cook H et al (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389:2117–2127CrossRefGoogle Scholar
  8. 8.
    Floege J (2011) The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis 58:992–1004CrossRefGoogle Scholar
  9. 9.
    Floege J, Eitner F (2011) Current therapy for IgA nephropathy. J Am Soc Nephrol 22(10):1785.  https://doi.org/10.1681/ASN.2011030221 CrossRefPubMedGoogle Scholar
  10. 10.
    Floege J, Feehally J (2016) IgA-Nephropathy: the Mucosa-kidney axis. Nat Rev Nephrol 12:147–156.  https://doi.org/10.1038/nrneph.2015.208 CrossRefPubMedGoogle Scholar
  11. 11.
    Floege J, Feehally J (2013) Treatment of IgA nephropathy and Henoch-Schonlein nephritis. Nat Rev Nephrol 9:320–327CrossRefGoogle Scholar
  12. 12.
    Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112–S119CrossRefGoogle Scholar
  13. 13.
    Frisch G, Lin J, Rosenstock J et al (2005) Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 20:2139–2145CrossRefGoogle Scholar
  14. 14.
    Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305CrossRefGoogle Scholar
  15. 15.
    Hoxha E, Kneissler U, Stege G et al (2012) Enhanced expression of the M‑type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 82:797–804CrossRefGoogle Scholar
  16. 16.
    Iijima K, Sako M, Nozu K et al (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273–1281CrossRefGoogle Scholar
  17. 17.
    Johnson RJ, Nakagawa T, Jalal D et al (2013) Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 28:2221–2228CrossRefGoogle Scholar
  18. 18.
    Kim AH, Chung JJ, Akilesh S et al (2017) B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight 2.  https://doi.org/10.1172/jci.insight.81836 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kiryluk K, Li Y, Scolari F et al (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196CrossRefGoogle Scholar
  20. 20.
    Lafayette RA, Canetta PA, Rovin BH et al (2017) A randomized, controlled trial of Rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28:1306–1313CrossRefGoogle Scholar
  21. 21.
    Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318:432–442CrossRefGoogle Scholar
  22. 22.
    Mahajan A, Simoni J, Sheather SJ et al (2010) Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 78:303–309CrossRefGoogle Scholar
  23. 23.
    Munyentwali H, Bouachi K, Audard V et al (2013) Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 83(3):511.  https://doi.org/10.1038/ki.2012.444 CrossRefPubMedGoogle Scholar
  24. 24.
    Orth SR, Ritz E, Schrier RW (1997) The renal risks of smoking. Kidney Int 51:1669–1677CrossRefGoogle Scholar
  25. 25.
    Papeta N, Kiryluk K, Patel A et al (2011) APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 22:1991–1996CrossRefGoogle Scholar
  26. 26.
    Pozzi C, Andrulli S, Pani A et al (2010) Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21:1783–1790CrossRefGoogle Scholar
  27. 27.
    Rauen T, Eitner F, Fitzner C et al (2015) Intensive supportive care plus Immunosuppression in IgA nephropathy. N Engl J Med 373:2225–2236CrossRefGoogle Scholar
  28. 28.
    Sarcina C, Tinelli C, Ferrario F et al (2016) Changes in proteinuria and side effects of corticosteroids alone or in combination with Azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol 11:973–981CrossRefGoogle Scholar
  29. 29.
    Shankland SJ, Smeets B, Pippin JW et al (2014) The emergence of the glomerular parietal epithelial cell. Nat Rev Nephrol 10:158–173CrossRefGoogle Scholar
  30. 30.
    Tomas NM, Beck LH Jr., Meyer-Schwesinger C et al (2014) Thrombospondin type-1 domain-containing 7 A in idiopathic membranous nephropathy. N Engl J Med 371:2277–2287CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Nieren- und HochdruckkrankheitenUniklinik der RWTH AachenAachenDeutschland
  2. 2.Institut für PathologieUniklinik der RWTH AachenAachenDeutschland

Personalised recommendations